Success Metrics

Clinical Success Rate
90.6%

Based on 29 completed trials

Completion Rate
91%(29/32)
Active Trials
0(0%)
Results Posted
34%(10 trials)
Terminated
3(8%)

Phase Distribution

Ph phase_3
10
28%
Ph phase_1
6
17%
Ph phase_2
3
8%
Ph not_applicable
1
3%
Ph phase_4
15
42%

Phase Distribution

6

Early Stage

3

Mid Stage

25

Late Stage

Phase Distribution35 total trials
Phase 1Safety & dosage
6(17.1%)
Phase 2Efficacy & side effects
3(8.6%)
Phase 3Large-scale testing
10(28.6%)
Phase 4Post-market surveillance
15(42.9%)
N/ANon-phased studies
1(2.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.6%

29 of 32 finished

Non-Completion Rate

9.4%

3 ended early

Currently Active

0

trials recruiting

Total Trials

36

all time

Status Distribution
Active(1)
Completed(29)
Terminated(3)
Other(3)

Detailed Status

Completed29
unknown3
Terminated3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
36
Active
0
Success Rate
90.6%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (17.1%)
Phase 23 (8.6%)
Phase 310 (28.6%)
Phase 415 (42.9%)
N/A1 (2.9%)

Trials by Status

unknown38%
not_yet_recruiting13%
completed2981%
terminated38%

Recent Activity

Clinical Trials (36)

Showing 20 of 36 trialsScroll for more
NCT07472413Phase 3

Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project

Not Yet Recruiting
NCT02535416Phase 1

A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers

Completed
NCT06019728Phase 4

A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

Completed
NCT05946551Phase 3

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

Terminated
NCT06754410Phase 3

Efficacy of Antihistamine Drugs as Medical Expulsive Therapy Alone or in Combination With Alpha Blockers: A Prospective Randomized Controlled Study

Completed
NCT06039137

The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment

Completed
NCT00751166Phase 4

A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)

Terminated
NCT00751218Phase 4

A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)

Completed
NCT06126991Phase 1

Organ Protective Effect of Cetirizine In Patients With Severe Burns

Unknown
NCT02865018Phase 1

Neuromyelitis Optica (NMO) & Cetirizine

Completed
NCT04237090Phase 3

Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel

Completed
NCT03192488Phase 4

Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia

Completed
NCT04293822Phase 4

Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia

Unknown
NCT01241214Phase 2

Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis

Completed
NCT02543346Phase 4

Comparability and Standardization of Controlled Allergen Challenge Facilities

Completed
NCT01825655Phase 4

Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching

Terminated
NCT01484119Phase 3

Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis

Completed
NCT01916226Phase 4

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

Completed
NCT00490204Phase 3

Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis

Completed
NCT02447393Phase 1

Phase 1 Study of Levocetirizine

Completed

Drug Details

Intervention Type
DRUG
Total Trials
36